IBMX, Non-specific cAMP and cGMP inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Adenosine A1 Receptor also called ADORA1 alongside its counterparts adenosine receptors A2a (ADORA2A) A2b (ADORA2B) and A3 (A3AR) and the phosphodiesterases PDE1B and PDE1C along with sodium channels SCN1A SCN2A and SCN3A play a significant role in signal transduction. These receptors and enzymes interact with cAMP and cGMP molecules to modulate cellular responses while the sodium channels particularly Scn1a mediate electrical signaling in nerve cells. The molecular weight of many of these proteins varies widely for instance ADORA1 has an approximate mass of 37 kDa. These proteins are highly expressed in tissues such as the brain and heart contributing to diverse physiological processes.

Biological function summary

These proteins and receptors are integral to several cellular functions. For example adenosine receptors participate in the regulation of neurotransmitter release and cardiovascular functions. PDE1B and PDE1C hydrolyze cAMP and cGMP critical secondary messengers that influence vascular tone and neuronal signaling. Meanwhile sodium channels like SCN1A form parts of voltage-gated sodium channel complexes that are key for action potential generation and propagation in neurons.

Pathways

These proteins and receptors are incorporated into critical signaling routes. Adenosine receptors and phosphodiesterases are involved in G protein-coupled receptor signaling and cAMP-dependent pathways highlighting their role in maintaining cellular homeostasis and response to external stimuli. Sodium channels SCN1A SCN2A and SCN3A are prominent in pathways governing nervous system excitability and conductance with interconnected proteins including other channels and kinases that modulate neuronal activities.

These protein targets relate strongly to neurological and cardiovascular conditions. For instance mutations in SCN1A are closely linked to epilepsy while dysregulation in adenosine receptor signaling can contribute to arrhythmias or heart failure. The phosphodiesterase inhibitors including compounds like IBMX (isobutylmethylxanthine) affect cAMP and cGMP pathways and can overlap with therapeutic interventions targeting these disorders. These associations highlight the need for precise modulation of their activity to mitigate disease effects.